Dr Graham Robertson has been a Research Associate at Strathclyde University since 2015. He previously studied Electronic and Electrical Engineering at Strathclyde before completing an EngD in Medical Devices by developing microfluidic platforms for neuroscience research. Since then his research has focussed on new techniques for modelling neurodegenerative conditions on-a-chip such as stroke as well as Alzheimer’s and Parkinson’s disease. Recently he has also been involved in optimising larger-throughput cancer screening devices.

• A microfluidics based drug screening platform for human tau mutation neurons
• Feasibility study to use enhanced fluorescent imaging and microfluidic technology for high-throughput drug screening of patient derived tumour cell models
• Developing an assay to measure neuron-to-neuron spread of α-synuclein pathology on a microfluidics platform

• G Robertson, TJ Bushell, and M Zagnoni, "Chemically induced synaptic activity between mixed primary hippocampal co-cultures in a microfluidic system", Integrative Biology 6 (6), 636-644, 2014. DOI: 10.1039/C3IB40221E
• AJ Samson, G Robertson, M Zagnoni, and CN Connolly "Neuronal networks provide rapid neuroprotection against spreading toxicity", Scientific reports 6, 33746, 2016. DOI: 10.1038/srep33746
• C MacKerron, G Robertson, M Zagnoni, and TJ Bushell "A Microfluidic Platform for the Characterisation of CNS Active Compounds", Scientific Reports 7 (1), 15692, 2017. DOI: 10.1038/s41598-017-15950-0
• L Ritchie, R Tate, LH Chamberlain, G Robertson, M Zagnoni, T Sposito, ... "Toll-like receptor 3 activation impairs excitability and synaptic activity via TRIF signalling in immature rat and human neurons", Neuropharmacology 135, 1-10, 2018. DOI: 10.1016/j.neuropharm.2018.02.025